Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development
Authors
Keywords
Advanced squamous cell carcinoma (SCC), Checkpoint kinase 1 and 2, CHK inhibitors, CHK1, CHK2, LY2606368, Ovarian cancer, PARP inhibitors, Prexasertib
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-11
DOI
10.1007/s00280-019-03950-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma
- (2018) David S. Hong et al. CLINICAL CANCER RESEARCH
- Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
- (2018) Jung-Min Lee et al. LANCET ONCOLOGY
- A dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors
- (2018) Satoru Iwasa et al. CANCER SCIENCE
- Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition
- (2018) Brittany Haynes et al. CANCER TREATMENT REVIEWS
- Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors
- (2017) Hani M. Babiker et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells
- (2017) Gwenola Manic et al. GUT
- Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma
- (2017) Ling Zeng et al. MOLECULAR CANCER THERAPEUTICS
- Kilogram-scale prexasertib monolactate monohydrate synthesis under continuous-flow CGMP conditions
- (2017) Kevin P. Cole et al. SCIENCE
- Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer
- (2017) Ethan Brill et al. Oncotarget
- Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
- (2016) Jeffrey R. Infante et al. CLINICAL CANCER RESEARCH
- Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer
- (2016) Giorgio Scagliotti et al. INVESTIGATIONAL NEW DRUGS
- Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
- (2016) David Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors
- (2016) Emiliano Calvo et al. ONCOLOGY
- Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
- (2015) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
- (2015) C. King et al. MOLECULAR CANCER THERAPEUTICS
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
- (2014) Edward Sausville et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CHK2 kinase in the DNA damage response and beyond
- (2014) L. Zannini et al. Journal of Molecular Cell Biology
- The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design
- (2013) Ruth Thompson et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours
- (2013) Takashi Seto et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube-Derived High-Grade Serous Ovarian Cancers
- (2013) A. M. Karst et al. CANCER RESEARCH
- ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA
- (2013) Luis Ignacio Toledo et al. CELL
- Checkpoint kinase 1 in DNA damage response and cell cycle regulation
- (2013) Mallikarjun Patil et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Roles of Chk1 in cell biology and cancer therapy
- (2013) Youwei Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy
- (2013) S. McNeely et al. PHARMACOLOGY & THERAPEUTICS
- Replication fork dynamics and the DNA damage response
- (2012) Rebecca M. Jones et al. BIOCHEMICAL JOURNAL
- The Mre11 Nuclease Is Critical for the Sensitivity of Cells to Chk1 Inhibition
- (2012) Ruth Thompson et al. PLoS One
- Claspin and Chk1 regulate replication fork stability by different mechanisms
- (2011) Jennifer Scorah et al. CELL CYCLE
- Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication
- (2011) C. S. Sorensen et al. NUCLEIC ACIDS RESEARCH
- New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
- (2010) Y. Dai et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More